BR0213821A - Conjugados de polìmero/peptìdeo timosina alfa 1 - Google Patents

Conjugados de polìmero/peptìdeo timosina alfa 1

Info

Publication number
BR0213821A
BR0213821A BR0213821-2A BR0213821A BR0213821A BR 0213821 A BR0213821 A BR 0213821A BR 0213821 A BR0213821 A BR 0213821A BR 0213821 A BR0213821 A BR 0213821A
Authority
BR
Brazil
Prior art keywords
polymer
peptide
peptide conjugates
thymosin alfa
administered
Prior art date
Application number
BR0213821-2A
Other languages
English (en)
Inventor
Alfred R Rudolph
Cynthia W Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of BR0213821A publication Critical patent/BR0213821A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

"CONJUGADOS DE POLìMERO/PEPTìDIO TIMOSINA ALFA 1". Uma composição farmacêutica inclui um conjugado fisiologicamente ativo incluindo um peptídio timosina alfa 1 (TA1) conjugado a um material que aumente a meia-vida do peptídio TA1 no soro de um paciente quando o conjugado for administrado ao paciente. O material pode ser um polímero substancialmente não antigênico. Em um método da invenção, o polímero substancialmente não antigênico está conjugado a um peptídio da TA1. As composições de acordo com a invenção são administradas a pacientes que estejam necessitando de estimulação imunológica.
BR0213821-2A 2001-11-01 2002-11-01 Conjugados de polìmero/peptìdeo timosina alfa 1 BR0213821A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33087001P 2001-11-01 2001-11-01
PCT/US2002/035094 WO2003037272A2 (en) 2001-11-01 2002-11-01 Thymosin alpha 1 peptide/polymer conjugates

Publications (1)

Publication Number Publication Date
BR0213821A true BR0213821A (pt) 2004-08-31

Family

ID=23291654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213821-2A BR0213821A (pt) 2001-11-01 2002-11-01 Conjugados de polìmero/peptìdeo timosina alfa 1

Country Status (17)

Country Link
US (2) US7297676B2 (pt)
EP (1) EP1455766B1 (pt)
JP (1) JP2005511553A (pt)
KR (1) KR20050042230A (pt)
CN (1) CN100536910C (pt)
AT (1) ATE549036T1 (pt)
AU (1) AU2002353964B2 (pt)
BR (1) BR0213821A (pt)
CA (1) CA2465874A1 (pt)
EA (1) EA008703B1 (pt)
IL (1) IL161670A0 (pt)
MX (1) MXPA04004188A (pt)
NO (1) NO20042055L (pt)
NZ (1) NZ532719A (pt)
PL (1) PL373795A1 (pt)
UA (1) UA78726C2 (pt)
WO (1) WO2003037272A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050086819A (ko) * 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
PL1639011T3 (pl) * 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
CN1314708C (zh) * 2004-05-24 2007-05-09 华东师范大学 一种人α1－胸腺肽的复合物及其制备方法
CN100500844C (zh) * 2005-03-07 2009-06-17 上海普洛康裕药物研究院有限公司 重组胸腺素α1在大肠杆菌中的高分泌表达和分离纯化
CN100577685C (zh) 2005-11-10 2010-01-06 中国人民解放军军事医学科学院毒物药物研究所 长效胸腺素α1的聚乙二醇化修饰物
CN101062950B (zh) * 2006-04-25 2010-04-21 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2344199A1 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
SI2849798T1 (sl) * 2012-05-18 2021-08-31 Replicor Inc. Oligonukleotidni kelatni kompleksni polipeptidni sestavki in postopki

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
DK0730470T3 (da) 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU6078899A (en) * 1998-10-13 2000-05-01 Novozymes A/S A modified polypeptide with reduced immune response
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1279405A1 (en) * 2000-03-30 2003-01-29 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins

Also Published As

Publication number Publication date
EA008703B1 (ru) 2007-06-29
IL161670A0 (en) 2004-09-27
KR20050042230A (ko) 2005-05-06
EP1455766A4 (en) 2008-11-05
EA200400592A1 (ru) 2004-12-30
US7297676B2 (en) 2007-11-20
WO2003037272A3 (en) 2003-11-20
US20080152668A1 (en) 2008-06-26
MXPA04004188A (es) 2004-07-08
EP1455766B1 (en) 2012-03-14
PL373795A1 (en) 2005-09-19
UA78726C2 (en) 2007-04-25
CN1582162A (zh) 2005-02-16
NZ532719A (en) 2005-11-25
EP1455766A2 (en) 2004-09-15
JP2005511553A (ja) 2005-04-28
WO2003037272A2 (en) 2003-05-08
CN100536910C (zh) 2009-09-09
ATE549036T1 (de) 2012-03-15
NO20042055L (no) 2004-05-18
CA2465874A1 (en) 2003-05-08
US20040248792A1 (en) 2004-12-09
AU2002353964B2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
MXPA05005330A (es) Composiciones y formulaciones de gastrina, y metodos de uso y preparacion.
AR008378A1 (es) Conjudados de interferon
TW200711657A (en) Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
TR200002299T2 (tr) Epotilon kompozisyonları.
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
AU1385699A (en) Novel conjugates of rgd-containing peptides and endogenous carriers
BR9607336A (pt) Composições de aminoácidos e utilidades das mesmas em nutrição clinica
MY139203A (en) Pharmaceutical composition
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
DK1173476T3 (da) Funktionelle sojabönneproteiner
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
BR0213823A (pt) Método de administração de um peptìdeo timosina alfa 1
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
DE60036199D1 (de) Proteaseresistente flint-analoge
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
BR0207017A (pt) Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida
RU2350351C2 (ru) Композиции и лекарственные формы на основе гастрина, методы применения и получения
Mezö et al. Properties of GnRH conjugates in vivo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.